Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index; 8 of the 54 sources its claims cite were checked for support.

Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature

Open access
Kistler, Kristin D, Nalysnyk, Luba, Rotella, Philip, Esser, Dirk · 2014 · BMC Pulmonary Medicine

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a distinct form of interstitial pneumonia with unknown origin and poor prognosis. Current pharmacologic treatments are limited and lung transplantation is a viable option for appropriate patients. The aim of this review was to summarize lung transplantation survival in IPF patients overall, between single (SLT) vs. bilateral lung transplantation (BLT), pre- and post Lung Allocation Score (LAS), and summarize wait-list survival. METHODS: A systematic review of English-language studies published in Medline or Embase between 1990 and 2013 was performed. Eligible studies were those of observational design reporting survival post-lung transplantation or while on the wait list among IPF patients. RESULTS: Median survival post-transplantation among IPF patients is estimated at 4.5 years. From ISHLT and OPTN data, one year survival ranged from 75% - 81%; 3-year: 59% - 64%; and 5-year: 47% - 53%. Post-transplant survival is lower for IPF vs. other underlying pre-transplant diagnoses. The proportion of IPF patients receiving BLT has steadily increased over the last decade and a half. Unadjusted analyses suggest improved long-term survival for BLT vs. SLT; after adjustment for patient characteristics, the differences tend to disappear. IPF patients account for the largest proportion of patients on the wait list and while wait list time has decreased, the number of transplants for IPF patients has increased over time. OPTN data show that wait list mortality is higher for IPF patients vs. other diagnoses. The proportion of IPF patients who died while awaiting transplantation ranged from 14% to 67%. While later transplant year was associated with increased survival, no significant differences were noted pre vs. post LAS implementation; however a high LAS vs low LAS was associated with decreased one-year survival. CONCLUSIONS: IPF accounts for the largest proportion of patients awaiting lung transplants, and IPF is associated with higher wait-list and post-transplant mortality vs. other diagnoses. Improved BLT vs. SLT survival may be the result of selection bias. Survival pre- vs. post LAS appears to be similar except for IPF patients with high LAS, who have lower survival compared to pre-LAS. Data on post-transplant morbidity outcomes are sparse.

Overview

CoChat Summary

TL;DR

This systematic review found that lung transplantation offers a survival benefit for IPF patients, but their post-transplant and wait-list mortality remain worse than for other diagnoses. Evidence suggested better unadjusted outcomes for bilateral over single lung transplantation, but those differences often disappeared after adjustment, pointing to likely selection bias.

Key findings

  • The review included 54 publications; the literature search identified 1,375 citations, screened 385 full-text articles, and excluded 331 at full-text review.
  • Among 8,528 IPF patients transplanted from 1990 to 2011 in ISHLT data, median survival was 4.5 years; survival was 75% at 1 year, 59% at 3 years, 47% at 5 years, and 24% at 10 years.
  • In OPTN data, IPF patients’ 1-, 3-, and 5-year post-transplant survival ranged from 75%–81%, 59%–64%, and 47%–53%, respectively; post-transplant survival was lower for IPF than for CF, COPD, or alpha-1 antitrypsin deficiency.
  • Wait-list burden was high: in 2011, IPF accounted for 46.1% of lung transplant wait-list patients in the US, and the proportion who died while waiting ranged from 14% to 67% across studies; OPTN wait-list mortality was higher for IPF than for other diagnoses.
  • For BLT vs. SLT, unadjusted analyses often favored BLT: in one OPTN analysis of 3,830 IPF patients, mean survival was 8.34 years for BLT vs. 7.37 years for SLT, but after adjustment the difference was no longer statistically significant (HR 0.92, 95% CI 0.81–1.06).

Methods

  • Systematic review of English-language observational studies in MEDLINE/EMBASE from 1990 to March 2013, supplemented by manual reference checking and data from ISHLT and OPTN websites.
  • Included studies had to report on at least 10 IPF patients who underwent lung transplantation and report survival post-transplant or while waiting.
  • The review extracted study-, patient-, and outcome-level data; one investigator extracted data and a second independently checked it for completeness and accuracy.

Limitations

  • The paper states that data on post-transplant morbidity and resource use are sparse.
  • The paper also states that a limitation is the lack of actual confirmation of IPF in most of the studies.
  • Evident from the text: much of the evidence comes from observational studies, so comparisons such as BLT vs. SLT and pre- vs. post-LAS are vulnerable to selection bias and confounding, which the authors explicitly discuss.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1471-2466-14-139

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study attrition. *Data from the OPTN and ISHLT websites were also included.
Figure 1 Study attrition. *Data from the OPTN and ISHLT websites were also included.CC BY · PubMed Central
Figure 2 Proportion of IPF patients receiving single vs. Bilateral lung transplants from 1997 – 2011, ISHLT data.
Figure 2 Proportion of IPF patients receiving single vs. Bilateral lung transplants from 1997 – 2011, ISHLT data.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 34 Not checked · 18 Own results and interpretations

25 more claims

Create a free account to see all 58 claims and to verify the 6 references still open.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 77 references

Research works printed but not linked: 1

  1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR): OPTN/SRTR 2011 Annual Data Report. 2012, Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation

Cited by

See all 151

Metadata

Authors
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D.
Affiliations
Boehringer Ingelheim (Germany) (DE)
Corresponding author
Kistler, Kristin D
Venue
BMC Pulmonary Medicine
Published
2014-08-16
Volume
14
Issue
1
Pages
139-139
ISSN
1471-2466 (ISSN-L)
OpenAlex
W2039943389
Cited by
151
References
77
Citations by year
2026: 4 · 2025: 6 · 2024: 16 · 2023: 8 · 2022: 13 · 2021: 15 · 2020: 13 · 2019: 13 · 2018: 25 · 2017: 18 · 2016: 11 · 2015: 7 · 2014: 1
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • BMC Pulmonary Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, lung transplantation, bilateral lung transplantation, single lung transplantation, lung allocation score, waitlist mortality, post-transplant survival, interstitial lung disease, OPTN registry, ISHLT registry
MeSH terms
Graft Survival, Humans, Waiting Lists, Survival Rate, Lung Transplantation, Idiopathic Pulmonary Fibrosis, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. https://app.cochat.ai/papers/10.1186/1471-2466-14-139
The paper
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014). Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulmonary Medicine. https://doi.org/10.1186/1471-2466-14-139

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.